Tag Archives: medical affairs
Leveraging Medical Analytics for Better Outcomes
The healthcare industry is witnessing a transformative shift fueled by advanced medical analytics. Imagine unlocking insights that redefine strategies, optimize product launches, and ultimately enhance patient outcomes and care models. It’s not just a vision—it’s a reality for forward-thinking Medical
How Elite Medical Affairs Teams Help Drive a Successful Pharma Product Launch
A highly regulated marketplace, coupled with intensifying competition, have pushed the Medical Affairs function into a significant launch role that extends from the pre-launch phases to well beyond market entry. Best-in-class Medical Affairs groups can become a kind of conduit
Apple & Amazon Have Entered Healthcare: How Will Medical Affairs Work with Large Employers?
Apple’s announcement that it will begin providing healthcare to its employees and families offers one more reason that Medical Affairs groups should ramp up their efforts to work with Large Employer groups. Apple’s announcement for AC Wellness follows on the heels of
Relationships Matter: To be Effective, Medical Information Groups in Pharmaceutical Companies Must Forge Collaborative Relationships with other Internal Groups such as Legal
Within the pharmaceutical sector, medical information groups shoulder great responsibilities. The principal role of medical information groups, which are typically part of the medical affairs organization, is responding to questions about products from external groups such as physicians. While this
Achieving Better Advocacy Group Relationships a Critical Piece of Resurgent Disease State Awareness Drive in Pharmaceutical Industry
When it comes to informing physicians and patients about new therapies, disease awareness programs have experienced a rebirth in the pharmaceutical industry. For decades, disease awareness campaigns were a part of the playbook for educating physicians and patients about new
Pharma Executive Talks Timing, Targeting and Trouble for Disease State Awareness Campaigns
In the pharmaceutical sector, disease state awareness campaigns are one of the few ways to reach patients and physicians before a product is approved. In essence, they set the table for future marketing efforts at product launch and post-launch. While
5 Important Trends Shaping Pharma Business in 2016
In a sector as fast-changing as biopharmaceuticals, it’s important to look beyond today’s hot topics to identify the long-term factors which are really driving change in the industry. From a list that could include a hundred headline-grabbing trends, we’ve pinned
Creating and Maintaining a Strategic KOL Management and Engagement System
Across the pharmaceutical sector, regulatory and access issues have reshaped interactions with Key Opinion Leaders (KOLs). And with KOL interactions affecting everything from clinical development to product launch, the issue of strategically managing these critical exchanges looms large for small
Role of Medical Affairs Increasing in Oncology Launch
The Medical Affairs function plays a vital role in a host of oncology activities, including identification and engagement of Key Thought Leaders to guidance of commercial strategies and launch resources management. It is becoming increasingly apparent that a successful launch
Best Practices Hosting 6th Medical Affairs Consortium on HEOR
Best Practices will be hosting the sixth roundtable of our Medical Affairs Consortium on Thursday (May 28th) from 11:00AM-12:30PM (EST) via a virtual roundtable to discuss “Medical Affairs’ Role in Health Economics & Outcomes Research.” This is the final roundtable
Exclusive: Key Findings from Best Practices’ 5th Medical Affairs Consortium
Best Practices recently completed the second roundtable of our 2014-2015 Medical Affairs Consortium. The roundtable addressed the topic of “Medical Affairs Launch Support.” The roundtable brought together executives from 13 leading pharmaceutical organizations. Some exclusive key findings from the discussion
Top Trends in 2015 – Is Your Organization Prepared?
2015 is here & with the New Year comes many new trends and topics of discussion. With the increasing importance of payers and high demand on evidence-based information, it is clear that there are many shifts happening in the pharmaceutical,
Medical Affairs Consortium: Impact Measures, Globalization & Compliance
On November 6, 2014 Best Practices, LLC hosted the 1st roundtable of the 2014-2015 Medical Affairs’ Consortium. The roundtable brought together leaders from: Baxter, Crescendo, Eli Lilly, Genentech, Incyte Corporation, Jazz Pharmaceuticals, Pfizer, Santen Inc., Teva, and Upsher-Smith. Leaders from
Best Practices’ Hosting Medical Affairs Consortium Roundtable Thursday, Nov. 6
Best Practices designed the Medical Affairs Consortium to provide Medical Affairs leaders with a forum for sharing insights about the key challenges they face. The consortium has developed a mechanism for creating and sharing solutions through three virtual roundtable discussions